203 related articles for article (PubMed ID: 20939761)
21. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Anthes JC; Chapman RW; Richard C; Eckel S; Corboz M; Hey JA; Fernandez X; Greenfeder S; McLeod R; Sehring S; Rizzo C; Crawley Y; Shih NY; Piwinski J; Reichard G; Ting P; Carruthers N; Cuss FM; Billah M; Kreutner W; Egan RW
Eur J Pharmacol; 2002 Aug; 450(2):191-202. PubMed ID: 12206858
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological characterization of senktide-induced tail whips.
Nordquist RE; Ballard TM; Algeyer B; Pauly-Evers M; Ozmen L; Spooren W
Neuropharmacology; 2010 Jan; 58(1):259-67. PubMed ID: 19540857
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of activation of peripheral and spinal tachykinin neurokinin(3) receptors on the micturition reflex in rats.
Kamo I; Chancellor MB; de Groat WC; Yoshimura N
J Urol; 2005 Aug; 174(2):776-81. PubMed ID: 16006975
[TBL] [Abstract][Full Text] [Related]
24. Tachykinin NK3 and NK1 receptor activation elicits secretion from porcine airway submucosal glands.
Phillips JE; Hey JA; Corboz MR
Br J Pharmacol; 2003 Jan; 138(1):254-60. PubMed ID: 12522097
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
Dawson LA; Langmead CJ; Dada A; Watson JM; Wu Z; de la Flor R; Jones GA; Cluderay JE; Southam E; Murkitt GS; Hill MD; Jones DN; Davies CH; Hagan JJ; Smith PW
Eur J Pharmacol; 2010 Feb; 627(1-3):106-14. PubMed ID: 19879867
[TBL] [Abstract][Full Text] [Related]
26. Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer.
Jordan RE; Smart D; Grimson P; Suman-Chauhan N; McKnight AT
Br J Pharmacol; 1998 Oct; 125(4):761-6. PubMed ID: 9831912
[TBL] [Abstract][Full Text] [Related]
27. Increased blocking activity of combined tachykinin NK1- and NK2-receptor antagonists on hyperventilation-induced bronchoconstriction in the guinea pig.
Corboz MR; Fernandez X; Hey JA
Pulm Pharmacol Ther; 2008; 21(1):67-72. PubMed ID: 17239637
[TBL] [Abstract][Full Text] [Related]
28. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
29. Involvement of enhanced neurokinin NK3 receptor expression in the severe asthma guinea pig model.
Mukaiyama O; Morimoto K; Nosaka E; Takahashi S; Yamashita M
Eur J Pharmacol; 2004 Sep; 498(1-3):287-94. PubMed ID: 15364007
[TBL] [Abstract][Full Text] [Related]
30. Activity of SR 142801 at peripheral tachykinin receptors.
Patacchini R; Barthò L; Holzer P; Maggi CA
Eur J Pharmacol; 1995 May; 278(1):17-25. PubMed ID: 7545122
[TBL] [Abstract][Full Text] [Related]
31. Tachykinin NK(3) receptor agonists induced microvascular leakage hypersensitivity in the guinea-pig airways.
Daoui S; Ahnaou A; Naline E; Emonds-Alt X; Lagente V; Advenier C
Eur J Pharmacol; 2001 Dec; 433(2-3):199-207. PubMed ID: 11755153
[TBL] [Abstract][Full Text] [Related]
32. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Sarau HM; Griswold DE; Potts W; Foley JJ; Schmidt DB; Webb EF; Martin LD; Brawner ME; Elshourbagy NA; Medhurst AD; Giardina GA; Hay DW
J Pharmacol Exp Ther; 1997 Jun; 281(3):1303-11. PubMed ID: 9190866
[TBL] [Abstract][Full Text] [Related]
33. Evidence for modulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbil mesencephalic cell cultures.
Alonso R; Fournier M; Carayon P; Petitpretre G; Le Fur G; Soubrié P
Eur J Neurosci; 1996 Apr; 8(4):801-8. PubMed ID: 9081631
[TBL] [Abstract][Full Text] [Related]
34. Localization of Fos-like immunoreactivity induced by the NK3 tachykinin receptor agonist, senktide, in the guinea-pig brain.
Yip J; Chahl LA
Br J Pharmacol; 1997 Oct; 122(4):715-25. PubMed ID: 9375969
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist.
Emonds-Alt X; Proietto V; Steinberg R; Advenier C; Daoui S; Naline E; Gueudet C; Michaud JC; Oury-Donat F; Poncelet M; Vilain P; Le Fur G; Maffrand JP; Soubrié P; Pascal M
Can J Physiol Pharmacol; 2002 May; 80(5):482-8. PubMed ID: 12056557
[TBL] [Abstract][Full Text] [Related]
36. Tachykinin NK(3)receptor involvement in anxiety.
Ribeiro SJ; Teixeira RM; Calixto JB; De Lima TC
Neuropeptides; 1999 Apr; 33(2):181-8. PubMed ID: 10657489
[TBL] [Abstract][Full Text] [Related]
37. A novel role for tachykinin neurokinin-3 receptors in regulation of human bronchial Ganglia neurons.
Myers AC; Goldie RG; Hay DW
Am J Respir Crit Care Med; 2005 Feb; 171(3):212-6. PubMed ID: 15477495
[TBL] [Abstract][Full Text] [Related]
38. Permissive role of neurokinin NK(3) receptors in NK(1) receptor-mediated activation of the locus coeruleus revealed by SR 142801.
Bert L; Rodier D; Bougault I; Allouard N; Le-Fur G; Soubrié P; Steinberg R
Synapse; 2002 Jan; 43(1):62-9. PubMed ID: 11746734
[TBL] [Abstract][Full Text] [Related]
39. Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: new tools for investigating neurokinin function.
Hagan RM; Ireland SJ; Jordan CC; Beresford IJ; Deal MJ; Ward P
Neuropeptides; 1991 Jun; 19(2):127-35. PubMed ID: 1719445
[TBL] [Abstract][Full Text] [Related]
40. Neurokinin receptors in the guinea pig ileum.
Nguyen-Le XK; Nguyen QT; Gobeil F; Jukic D; Chrétien L; Regoli D
Pharmacology; 1996 Jan; 52(1):35-45. PubMed ID: 8966201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
